Cryo-Cell International (CCEL) vs Progyny (PGNY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Progyny (PGNY) has outperformed Cryo-Cell International (CCEL) over the past year, gaining 37.8% versus a loss of 11.3%. Over five years, PGNY leads with a -50.8% price change compared with -70.3% for CCEL. Progyny is the larger company by market cap ($2.13 billion vs $32.3 million), about 66.1 times the size.
On valuation, Progyny trades at a lower forward P/E (12.0x vs 200.0x for Cryo-Cell International).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CCEL | PGNY |
|---|---|---|
| Share price | $4.00 | $27.78 |
| Market cap | $32.25M | $2.13B |
| 1-day change | +1.71% | +0.83% |
| YTD return | +13.66% | +7.28% |
| 1-year return | -11.34% | +37.75% |
| 5-year return | -70.27% | -50.79% |
| P/E ratio (TTM) | — | 30.20 |
| Forward P/E | 200.00 | 11.98 |
| EPS (TTM) | $-0.31 | $0.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.90 | $33.07 |
| 52-week low | $2.72 | $16.10 |
| Distance from 52-week high | -18.37% | -15.98% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +23.90% |
| Average volume | 23.32K | 1.14M |
| Shares outstanding | 8.06M | 76.73M |
| Employees | — | 835 |
| Sector | Health Care | Health Care |
| Industry | Misc Health and Biotechnology Services | Misc Health and Biotechnology Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Progyny is about 66.1 times larger than Cryo-Cell International by market value ($2.13B vs $32.25M).
- PGNY has outperformed CCEL by 49.1 percentage points over the past year.
About Progyny
PGNY stock →Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists.
Health Care · Misc Health and Biotechnology Services · 835 employees
CCEL vs PGNY FAQ
Which is bigger, Cryo-Cell International or Progyny?
Progyny (PGNY) is larger, with a market capitalization of $2.13B compared with $32.25M for Cryo-Cell International (CCEL).
Which stock has performed better over the past year, CCEL or PGNY?
PGNY returned +37.75% over the past 12 months, compared with -11.34% for CCEL (price return, excluding dividends). Past performance does not predict future results.
Are Cryo-Cell International and Progyny in the same industry?
Yes. Both are classified in the Misc Health and Biotechnology Services industry within the Health Care sector.